AstraZeneca (LON:AZN) Given Buy Rating at Berenberg Bank

AstraZeneca (LON:AZN - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Berenberg Bank in a research report issued on Wednesday, Marketbeat.com reports. They presently have a GBX 140 ($1.81) target price on the biopharmaceutical company's stock. Berenberg Bank's price objective points to a potential downside of 98.75% from the stock's previous close.

Other equities analysts have also issued reports about the company. Shore Capital restated a "buy" rating on shares of AstraZeneca in a report on Friday, March 7th. JPMorgan Chase & Co. reissued an "overweight" rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of GBX 7,542.80 ($97.53).

AstraZeneca Stock Down 1.9 %

Shares of AZN traded down GBX 220.67 ($2.85) during mid-day trading on Wednesday, hitting £111.95 ($144.75). 1,678,315 shares of the company's stock were exchanged, compared to its average volume of 22,864,193. The stock has a market cap of £215.40 billion, a price-to-earnings ratio of 30.69, a P/E/G ratio of 0.86 and a beta of 0.17. The firm has a fifty day moving average of £115.86 and a two-hundred day moving average of £112.53. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. AstraZeneca has a twelve month low of GBX 9,670 ($125.03) and a twelve month high of £133.88 ($173.11).

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.